Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or New Mexico for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to New Mexico only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. New Mexico (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Masoud Khorsand-sahbaie (NPI 1629066097)

Field	Value
Entity Type	Individual
Organization	Masoud Khorsand-sahbaie
Address	407 W Country Club Rd
City	Roswell
State	NM
ZIP	88201
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	October 11, 2005

Payer Source	Total Paid
Medicare	$1.3M
Medicaid	$0

Key Findings

This provider is effectively a Medicare-focused hematology/oncology practice: total Medicare revenue is $1.3M and there is no Medicaid billing on file, so payer exposure is concentrated entirely in the Medicare population. The absence of Medicaid claims suggests limited engagement with state Medicaid managed care or fee-for-service beneficiaries.

Revenue is highly concentrated in a small number of codes: the precomputed top 3 Medicare codes account for 75.0% of the provider's Medicare revenue, driven predominantly by J9271 (pembrolizumab) which alone represents $672K or 56.1% of Medicare revenue. The next two top contributors are 78815 at $143K (11.9%) and 99214 at $83.4K (7.0%), underscoring a narrow revenue base around high-cost infusions, advanced imaging, and E/M visits.

The code mix and volumes indicate an oncology infusion and follow-up practice model: J9271 (16K claims, $42 avg paid/claim, $672K revenue) is the dominant single revenue driver and represents use of pembrolizumab immunotherapy, while 78815 (124 claims, $1153 avg paid/claim, $143K revenue) reflects regular reliance on PET/CT imaging for staging or response assessment. Supportive oncology services appear in office E/M (99214: 907 claims, $92 avg paid/claim, $83.4K) and chemotherapy administration codes (96413: 371 claims, $94 avg paid/claim, $34.9K), consistent with an active infusion clinic model.

Competitive standing on principal services is mixed: for J9271 the provider ranks #613 of 1841 nationally (66th percentile) and is described as having a typical, unremarkable volume for that drug, so they are a meaningful but not dominant national supplier of pembrolizumab. For 78815 they rank #1661 of 6566 (74th percentile; typical, unremarkable volume), while 99214 ranks #14579 of 479517 (97th percentile; notably above typical national volume), indicating relatively high office-visit activity compared with peers even though infusion drug volumes are more typical.

Operational profile is consistent with high-touch outpatient oncology management: very large counts for ancillary services (36415: 3.4K claims, $7 avg paid/claim, $23.5K revenue; 85025: 2.7K claims, $8 avg paid/claim, $21.3K; 80053: 2.2K claims, $10 avg paid/claim, $21.8K) and strong percentile ranks (36415 at the 99th percentile, 80053 and 85025 at the 98th percentile) suggest in-clinic phlebotomy and frequent laboratory monitoring accompany infusion care. These high ancillary volumes support the clinical intensity implied by the immunotherapy and imaging activity.

The provider’s Medicare mix creates exposure to shifts in high-cost drug utilization and imaging reimbursement: with J9271 accounting for 56.1% of Medicare revenue and the top three codes accounting for 75.0% of revenue, changes in utilization patterns, drug pricing, or payer coverage for pembrolizumab and PET/CT could materially affect overall revenue. This concentration suggests the practice’s financial performance is closely tied to oncology drug and imaging reimbursement trends rather than a broadly diversified procedure base.

The NPI tenure indicates an established practice footprint: the provider’s NPI was enumerated on 2005-10-11 (~21 years ago), consistent with a long-standing regional presence in Roswell, NM. Combined with the Medicare revenue profile and high ancillary volumes, the data portray a stable, experienced oncology clinician operating an outpatient infusion and diagnostic monitoring practice largely supported by Medicare patients.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

88 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	16,000	$40	$672K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	120	$1,150	$143K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	910	$90	$83.4K
J0897	Injection, denosumab, 1 mg	2,640	$20	$42.2K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	370	$90	$34.9K
J1439	Injection, ferric carboxymaltose, 1 mg	26,250	$1	$26.3K
36415	In this procedure, the provider inserts a needle into a vein to collect a blood sample.	3,360	$10	$23.5K
80053	The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel.	2,180	$10	$21.8K
85025	A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a…	2,660	$10	$21.3K
J0885	Injection, epoetin alfa, (for non-esrd use), 1000 units	3,380	$10	$20.3K

Showing 1–10 of 88

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 88 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. New Mexico Distribution

Masoud Khorsand-sahbaie — 5 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — New Mexico

Full comparison — all codes billed, vs. state median

88 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	2	10	9,400	$40	$469.6K
J0897	27	50	3,150	$20	$113.2K
78815	6	30	70	$600	$62.8K
83970	2	10	100	$40	$37.7K
J0885	3	10	7,080	$10	$35.8K
J1439	6	10	25,500	$1	$23.1K
96413	3	40	170	$90	$17.7K
82306	3	30	110	$30	$17K
93306	93	90	190	$60	$15.9K
A9552	6	20	100	$160	$15.1K

Showing 1–10 of 88

Related Providers

Other providers that share a Tax Identification Number (TIN) with Masoud Khorsand-sahbaie, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Masoud Khorsand- Sahbaie Md P A	NM	Hematology & Oncology Physician	$0	$8.1M
Aqeel Khan	IL	Psychiatry Physician	$2.2M	$3.5M
Timothy Fuller	TX	Ophthalmology Physician	$3.5M	$0
Sreedevi Daggubati	TX	Hematology & Oncology Physician	$2.8M	$0
Sunil Patel	TX	Ophthalmology Physician	$2.6M	$0
Mark Levitan	TX	Ophthalmology Physician	$2.5M	$0
Jason Bradley	TX	Interventional Cardiology Physician	$2.1M	$0
Charles Clark	TX	Ophthalmology Physician	$2.1M	$0
Colbert Perez	TX	Interventional Cardiology Physician	$2M	$0
Eric Zavaleta	TX	Ophthalmology Physician	$1.9M	$0

Nearby Providers

Other providers in the same ZIP code as Masoud Khorsand-sahbaie, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Aspire Developmental Services, LLC	NM	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$45.5M
Roswell Hospital Corporation	NM	General Acute Care Hospital	$0	$41.3M
Bca Medical Associates, PA	NM	Pediatrics Physician	$0	$41.2M
Lovelace Health System LLC	NM	General Acute Care Hospital	$0	$20.1M
Pathology Consultants Of New Mexico	NM	Anatomic Pathology Physician	$376.7K	$18M
Roswell Clinic Corp	NM	Family Medicine Physician	$0	$14.7M
La Casa De Buena Salud Inc	NM	Federally Qualified Health Center (FQHC)	$0	$11M
Agape Home Care LLC	NM	Supports Brokerage Agency	$0	$7.4M
Roswell Family Care, LLC	NM	Family Nurse Practitioner	$0	$6.3M
Home Medical Equipment Specialists LLC	NM	Durable Medical Equipment & Medical Supplies	$0	$6M

Masoud Khorsand-sahbaie — Billing Profile & Reimbursement Data

Sign up for Masoud Khorsand-sahbaie — Billing Profile & Reimbursement Data policy alerts

Masoud Khorsand-sahbaie — Billing Profile & Reimbursement Data

Sign up for Masoud Khorsand-sahbaie — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References